Evotec Finds New Partner for NMDA Drugs in Janssen Deal
By Nuala Moran
Monday, December 17, 2012
A year and a half after Roche AG handed back rights, Evotec AG has found a new home for its NMDA antagonist portfolio, in a licensing deal with Janssen Pharmaceuticals Inc. worth a potential $75 million up to launch.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.